February 20, 2019
Vaccine development has traditionally focused on targeting antigen to skin dendritic cells (DCs), which are thought to migrate to lymph nodes to initiate an immune response. However, new research suggests that these migratory skin DCs actually have an inhibitory role and instead that it is lymphoid-resident classical DCs (cDCs) activated by FMS-like tyrosine kinase 3 ligand (FLT3L) that drive vaccination-triggered immune responses. Read More